Background Community-acquired pneumonia (CAP) 2007 guidelines from the Infectious
Diseases Society of America (IDSA)/American Thoracic Society (ATS) recommend a …

In 2019, guidelines for the management of immunocompetent adults with community-
acquired pneumonia (CAP) were published jointly by the American Thoracic Society and the …

Objectives To assess the clinical effect of empirical treatment with narrow-spectrum ß-lactam
monotherapy (NSBM) versus broad-spectrum ß-lactam monotherapy (BSBM) in non-severe …

Background: In Asia, an estimated one million deaths are caused by communityacquired
pneumonia (CAP) each year. Despite the high mortality in elderly people, a large number of …

Community-acquired pneumonia (CAP) is a leading cause of death from an infectious cause
worldwide. Guideline-concordant antibiotic therapy initiated in a timely manner is associated …

OBJECTIVE To provide family physicians with a review of evidence supporting
fluoroquinolone therapy for defined patient populations with acute exacerbations of chronic …

Background Community‐acquired pneumonia (CAP), the sixth most common cause of death
worldwide, is a common condition representing a significant disease burden for the …

Objectives: The current treatment options for patients with community-acquired pneumonia
(CAP) often present a trade-off between the potential for treatment failure and safety …

Objectives: Current clinical practice guidelines, including those in south Asia, recommend
the addition of a macrolide to a broad‐spectrum antibiotic for the treatment of severe …

This study compared patients with moderate-to-severe community-acquired pneumonia
(CAP) requiring hospitalisation, who received initial therapy with either intravenous …